{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:43:07Z","timestamp":1793367787494,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1136\/ard-2022-222849","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T17:22:58Z","timestamp":1660324978000},"page":"154-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial"],"prefix":"10.1016","volume":"82","clinical-trial-number":[{"clinical-trial-number":"nct03031782","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03031782","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-2987","authenticated-orcid":false,"given":"Hermine I","family":"Brunner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Foeldvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Alexeeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3594-7387","authenticated-orcid":false,"given":"Nuray Aktay","family":"Ayaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Calvo Penades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-7720","authenticated-orcid":false,"given":"Ozgur","family":"Kasapcopur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vyacheslav G","family":"Chasnyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hufnagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbigniew","family":"\u017buber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5923-7051","authenticated-orcid":false,"given":"Grant","family":"Schulert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seza","family":"Ozen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelina","family":"Rakhimyanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athimalaipet","family":"Ramanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiaan","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betul","family":"Sozeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zholobova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruvie","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luminita","family":"Pricop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1604-0130","authenticated-orcid":false,"given":"Daniel","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8407-7782","authenticated-orcid":false,"given":"Nicolino","family":"Ruperto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-222849_bib1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3899\/jrheum.180168","article-title":"Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus","volume":"46","author":"Martini","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-222849_bib2","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/acr.24529","article-title":"Children with Enthesitis\u2010Related arthritis and possible benefits from treatments for adults with spondyloarthritis","volume":"74","author":"Weiss","year":"2022","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-222849_bib3","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3899\/jrheum.160197","article-title":"Predicting which children with juvenile idiopathic arthritis will have a severe disease course: results from the ReACCh-Out cohort","volume":"44","author":"Guzman","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-222849_bib4","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/annrheumdis-2018-213030","article-title":"Treating juvenile idiopathic arthritis to target: recommendations of an international Task force","volume":"77","author":"Ravelli","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222849_bib5","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/acr.22657","article-title":"A randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with Enthesitis-Related arthritis","volume":"67","author":"Burgos-Vargas","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-222849_bib6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.5606\/ArchRheumatol.2017.6067","article-title":"Interleukin-17A levels increase in serum of children with juvenile idiopathic arthritis","volume":"32","author":"Vijatov-Djuric","year":"2017","journal-title":"Arch Rheumatol"},{"key":"10.1136\/ard-2022-222849_bib7","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/art.38376","article-title":"Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression","volume":"66","author":"Menon","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222849_bib8","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-222849_bib9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/art.41477","article-title":"Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study","volume":"73","author":"Deodhar","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222849_bib10","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (future 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-222849_bib11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2013results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-222849_bib12","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1002\/art.27670","article-title":"Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs","volume":"62","author":"Ruperto","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-222849_bib13","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/art.20288","article-title":"A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate","volume":"50","author":"Ruperto","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-222849_bib14","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","article-title":"Preliminary definition of improvement in juvenile arthritis","volume":"40","author":"Giannini","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-222849_bib15","first-page":"1058","article-title":"Preliminary definition of disease flare in juvenile rheumatoid arthritis","volume":"29","author":"Brunner","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-222849_bib16","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/acr.20497","article-title":"American College of rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis","volume":"63","author":"Wallace","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-222849_bib17","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. pediatric rheumatology collaborative Study Group","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-222849_bib18","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/art.41390","article-title":"New medications are needed for children with juvenile idiopathic arthritis","volume":"72","author":"Brunner","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222849_bib19","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.3899\/jrheum.120642","article-title":"Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: the childhood arthritis and rheumatology research alliance registry","volume":"39","author":"Weiss","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-222849_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12969-017-0153-5","article-title":"Health-Related quality of life among Swedish children with juvenile idiopathic arthritis: parent-child discrepancies, gender differences and comparison with a European cohort","volume":"15","author":"Lundberg","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1136\/ard-2022-222849_bib21","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/annrheumdis-2018-213131","article-title":"Consensus-Based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the share initiative","volume":"77","author":"Constantin","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222849_bib22","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/acr.23870","article-title":"2019 American College of Rheumatology\/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for Non\u2010Systemic polyarthritis, sacroiliitis, and Enthesitis","volume":"71","author":"Ringold","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-222849_bib23","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/acr.23844","article-title":"Worse quality of life, function, and pain in children with enthesitis, irrespective of their juvenile arthritis category","volume":"72","author":"Rumsey","year":"2020","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-222849_bib24","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","article-title":"Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 future 2 study","volume":"56","author":"McInnes","year":"2017","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-222849_bib25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/acr2.11097","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5-year results from the phase 3 future 1 study","volume":"2","author":"Mease","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1136\/ard-2022-222849_bib26","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/acr.23111","article-title":"Secukinumab for long-term treatment of psoriatic arthritis: a two-year followup from a phase III, randomized, double-blind placebo-controlled study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-222849_bib27","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-222849_bib28","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/art.41528","article-title":"Efficacy and safety of tocilizumab for Polyarticular-Course juvenile idiopathic arthritis in the open-label two-year extension of a phase III trial","volume":"73","author":"Brunner","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222849_bib29","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/art.27431","article-title":"Long-Term safety and efficacy of abatacept in children with juvenile idiopathic arthritis","volume":"62","author":"Ruperto","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-222849_bib30","doi-asserted-by":"crossref","first-page":"620","DOI":"10.55563\/clinexprheumatol\/1u8y08","article-title":"Secukinumab in the treatment for patients with juvenile enthesitis related arthritis non-responsive to anti-TNF treatment according the juvenile spondyloarthritis disease activity index","volume":"40","author":"Baer","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-222849_bib31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/cpt.2155","article-title":"Il-17 inhibitors and inflammatory bowel diseases: a postmarketing study in Vigibase","volume":"110","author":"Petitpain","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1136\/ard-2022-222849_bib32","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3899\/jrheum.160717","article-title":"The juvenile psoriatic arthritis cohort in the CARRA registry: clinical characteristics, classification, and outcomes","volume":"44","author":"Zisman","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-222849_bib33","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/jdv.17002","article-title":"Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a phase 3 double-blind randomized, controlled trial","volume":"35","author":"Bodemer","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724086321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724086321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-222849","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:36:41Z","timestamp":1739522201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724086321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0003496724086321"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-222849","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-222849","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}